Cargando…
Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China
BACKGROUND: Coronavirus Disease 2019 (COVID-19) is an emerging and rapidly evolving disease, with no recommended effective anti-coronavirus drug treatment. Traditional Chinese Patent Medicines (CPMs) have, however, been widely used to treat COVID-19 in China, and a number of clinical practice result...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396557/ https://www.ncbi.nlm.nih.gov/pubmed/32848729 http://dx.doi.org/10.3389/fphar.2020.01066 |
_version_ | 1783565609439592448 |
---|---|
author | Zhuang, Wei Fan, Zheng Chu, Yanqi Wang, Haizheng Yang, Ying Wu, Li Sun, Nan Sun, Ge Shen, Yuqiao Lin, Xiaolan Guo, Guiming Xi, Shengyan |
author_facet | Zhuang, Wei Fan, Zheng Chu, Yanqi Wang, Haizheng Yang, Ying Wu, Li Sun, Nan Sun, Ge Shen, Yuqiao Lin, Xiaolan Guo, Guiming Xi, Shengyan |
author_sort | Zhuang, Wei |
collection | PubMed |
description | BACKGROUND: Coronavirus Disease 2019 (COVID-19) is an emerging and rapidly evolving disease, with no recommended effective anti-coronavirus drug treatment. Traditional Chinese Patent Medicines (CPMs) have, however, been widely used to treat COVID-19 in China, and a number of clinical practice results have shown them to have a significant role in its treatment. Consequently, numerous guidelines and expert consensus have recommended the use of CPMs to treat COVID-19. AIM OF THE STUDY: The objectives of this review are to provide up-to-date information on the pharmacology and clinical research on CPMs in the treatment of COVID-19, discuss the research findings, and to better guide clinical application and scientific research on CPMs in the treatment of COVID-19. METHODS: The frequencies of CPM recommendations by guidelines and expert consensus for treatment of COVID-19 in China were ranked. This report identifies the top 10 CPMs, which include Huoxiang Zhengqi capsule (HXZQC), Lianhua Qingwen capsule (LHQWC), Jinhua Qinggan granule (JHQGG), Shufeng Jiedu capsule (SFJDC), Tanreqing injection (TRQI), Xiyanping injection (XYPI), Xuebijing injection (XBJI), Shenfu injection (SFI), Shengmai injection (SMI), and Angong Niuhuang pill (AGNHP). Relevant studies from 2000 to 2020 on these top 10 CPMs, covering usage, dosage, mechanism, curative effect, and precautions, were collected from pharmacopoeia, reports, and theses via library and digital databases (including PubMed, CNKI, Google Scholar, Web of Science, and Elsevier). RESULTS: The properties of the top 10 CPMs included antiviral, antibacterial, anti-inflammatory, antipyretic and analgesic, anti-acute lung injury, anti-shock, immune regulation, and enhancement of pulmonary function. In addition, clinical research results and Chinese treatment data showed that the CPMs had good therapeutic efficacy in the treatment of COVID-19, and adverse reactions were minimal. CONCLUSIONS: Knowledge of the characteristics of the top 10 CPMs and precautions that should be taken may help clinicians to rationally improve therapeutic efficacy, and promote the role of Chinese Medicine in the control of the COVID-19 global epidemic. |
format | Online Article Text |
id | pubmed-7396557 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73965572020-08-25 Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China Zhuang, Wei Fan, Zheng Chu, Yanqi Wang, Haizheng Yang, Ying Wu, Li Sun, Nan Sun, Ge Shen, Yuqiao Lin, Xiaolan Guo, Guiming Xi, Shengyan Front Pharmacol Pharmacology BACKGROUND: Coronavirus Disease 2019 (COVID-19) is an emerging and rapidly evolving disease, with no recommended effective anti-coronavirus drug treatment. Traditional Chinese Patent Medicines (CPMs) have, however, been widely used to treat COVID-19 in China, and a number of clinical practice results have shown them to have a significant role in its treatment. Consequently, numerous guidelines and expert consensus have recommended the use of CPMs to treat COVID-19. AIM OF THE STUDY: The objectives of this review are to provide up-to-date information on the pharmacology and clinical research on CPMs in the treatment of COVID-19, discuss the research findings, and to better guide clinical application and scientific research on CPMs in the treatment of COVID-19. METHODS: The frequencies of CPM recommendations by guidelines and expert consensus for treatment of COVID-19 in China were ranked. This report identifies the top 10 CPMs, which include Huoxiang Zhengqi capsule (HXZQC), Lianhua Qingwen capsule (LHQWC), Jinhua Qinggan granule (JHQGG), Shufeng Jiedu capsule (SFJDC), Tanreqing injection (TRQI), Xiyanping injection (XYPI), Xuebijing injection (XBJI), Shenfu injection (SFI), Shengmai injection (SMI), and Angong Niuhuang pill (AGNHP). Relevant studies from 2000 to 2020 on these top 10 CPMs, covering usage, dosage, mechanism, curative effect, and precautions, were collected from pharmacopoeia, reports, and theses via library and digital databases (including PubMed, CNKI, Google Scholar, Web of Science, and Elsevier). RESULTS: The properties of the top 10 CPMs included antiviral, antibacterial, anti-inflammatory, antipyretic and analgesic, anti-acute lung injury, anti-shock, immune regulation, and enhancement of pulmonary function. In addition, clinical research results and Chinese treatment data showed that the CPMs had good therapeutic efficacy in the treatment of COVID-19, and adverse reactions were minimal. CONCLUSIONS: Knowledge of the characteristics of the top 10 CPMs and precautions that should be taken may help clinicians to rationally improve therapeutic efficacy, and promote the role of Chinese Medicine in the control of the COVID-19 global epidemic. Frontiers Media S.A. 2020-07-17 /pmc/articles/PMC7396557/ /pubmed/32848729 http://dx.doi.org/10.3389/fphar.2020.01066 Text en Copyright © 2020 Zhuang, Fan, Chu, Wang, Yang, Wu, Sun, Sun, Shen, Lin, Guo and Xi http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Zhuang, Wei Fan, Zheng Chu, Yanqi Wang, Haizheng Yang, Ying Wu, Li Sun, Nan Sun, Ge Shen, Yuqiao Lin, Xiaolan Guo, Guiming Xi, Shengyan Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China |
title | Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China |
title_full | Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China |
title_fullStr | Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China |
title_full_unstemmed | Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China |
title_short | Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China |
title_sort | chinese patent medicines in the treatment of coronavirus disease 2019 (covid-19) in china |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396557/ https://www.ncbi.nlm.nih.gov/pubmed/32848729 http://dx.doi.org/10.3389/fphar.2020.01066 |
work_keys_str_mv | AT zhuangwei chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina AT fanzheng chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina AT chuyanqi chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina AT wanghaizheng chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina AT yangying chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina AT wuli chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina AT sunnan chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina AT sunge chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina AT shenyuqiao chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina AT linxiaolan chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina AT guoguiming chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina AT xishengyan chinesepatentmedicinesinthetreatmentofcoronavirusdisease2019covid19inchina |